Eli Lilly and Company (NYSE:LLY) Trading Up 4.5% – Here’s Why

Eli Lilly and Company (NYSE:LLY) shares were up 4.5% during trading on Wednesday . The company traded as high as $1,292.65 and last traded at $1,280.6160. Approximately 4,402,831 shares were traded during trading, an increase of 41% from the average session volume of 3,111,745 shares. The stock had previously closed at $1,225.73.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: GLP-1 portfolio is outperforming Novo Nordisk. Lilly’s Q2 obesity and diabetes portfolio reportedly outpaced rival Novo Nordisk’s performance. Investors are also watching Lilly’s oral obesity treatments as it seeks to close or reverse Novo’s early lead in the weight-loss pill market. LLY’s Q2 GLP-1 Portfolio Compared With NVO’s
• Positive Sentiment: Pipeline activity is broadening beyond obesity. Lilly announced or advanced drug-development agreements involving neuroscience and ion-channel programs, including a collaboration with OmniAb and a transaction with AlzeCure that included a $10 million upfront payment. These deals strengthen Lilly’s access to potential Alzheimer’s, pain and other central-nervous-system therapies. Lilly Expands Neuroscience Reach With New Drug Deals
• Positive Sentiment: Key clinical programs are advancing. Updates on lepodisiran, LY4086940 and the oral-candidate formulation LY4065967 indicate continued progress in Lilly’s pipeline. Investors are particularly focused on retatrutide and other next-generation obesity and diabetes treatments as potential future growth drivers. Lilly Advances Oral Pipeline
• Neutral Sentiment: Analysts remain broadly constructive. Lilly screens favorably for long-term growth, with a consensus “Moderate Buy” rating and several price-target increases. However, commentary also emphasizes that much of the expected obesity-drug growth may already be reflected in the valuation. Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?
• Negative Sentiment: Competition and valuation are the main risks. Novo Nordisk remains a significant oral-obesity competitor, while Pfizer is developing a potential monthly obesity treatment that could eventually challenge leading GLP-1 drugs. Lilly’s premium earnings multiple increases sensitivity to clinical, regulatory or commercial setbacks. Pfizer’s Obesity Push
• Negative Sentiment: Insider selling is a minor headwind. EVP Patrik Jonsson sold 6,500 shares for approximately $7.6 million, though the transaction was executed under a pre-arranged Rule 10b5-1 plan, limiting its bearish significance. SEC Insider Transaction Filing

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Cantor Fitzgerald boosted their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Truist Financial upped their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Up 4.5%

The firm has a 50-day moving average price of $1,173.20 and a two-hundred day moving average price of $1,055.15. The company has a market capitalization of $1.21 trillion, a P/E ratio of 42.97, a PEG ratio of 1.39 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last three months. 0.14% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently bought and sold shares of LLY. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $30,000. Maseco LLP boosted its stake in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the last quarter. Finally, Aventus Investment Advisors Inc. increased its position in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.